Benzinga
Benzinga
Benzinga
lunedì, settembre 21

Akari Therapeutics PLC

AKTXNASDAQ
Trade with Public
Trade with Public
$9.38
-0.50-5.06%
In chiusura: Sep 17, 5:00 PM EST
$9.38
-0.49-5.01%
Pre-mercato: 4:01 AM EST
PanoramicaNotiziePrevisioni utiliEventiObiettivi di prezzoDati finanziariSentimentAzionariatoConfrontaOpzioniRapporto azionario

Akari Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Akari Therapeutics (AKTX).

Price Target Range — 4 Quarters

Analyst Consensus — 3 Analysts

3Buy
Consensus RatingBuy# Analysts3Avg. Consensus PT$32Upside to Avg. PT+244.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

Visualizza tutte le valutazioni →
DateFirmAnalystActionRating ChangePrice Target
Jul 20, 2026Maxim GroupJason McCarthyUpgradeHold→Buy$30
Apr 8, 2026Maxim GroupJason McCarthyDowngradeBuy→Hold—
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Maxim Group Upgrades Akari Therapeutics to Buy, Announces $30 Price Target

Maxim Group analyst Jason McCarthy upgrades Akari Therapeutics (NASDAQ:AKTX) from Hold to Buy and announces $30 price target.
Benzinga Newsdesk

PRO
Maxim Group Downgrades Akari Therapeutics to Hold

Maxim Group analyst Jason McCarthy downgrades Akari Therapeutics (NASDAQ:AKTX) from Buy to Hold.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Akari Therapeutics, Maintains $1.6 Price Target

HC Wainwright & Co. analyst Sean Lee reiterates Akari Therapeutics (NASDAQ:AKTX) with a Buy and maintains $1.6 price target.
Benzinga Newsdesk

PRO
Maxim Group Initiates Coverage On Akari Therapeutics with Buy Rating, Announces Price Target of $5

Maxim Group analyst Jason McCarthy initiates coverage on Akari Therapeutics (NASDAQ:AKTX) with a Buy rating and announces Price Target of $5.
Benzinga Newsdesk

Benzinga's Top Ratings Upgrades, Downgrades For December 5, 2022

Benzinga Insights

PRO
HC Wainwright & Co. Initiates Coverage On Akari Therapeutics with Buy Rating, Announces Price Target of $1.5

HC Wainwright & Co. analyst Sean Lee initiates coverage on Akari Therapeutics (NASDAQ:AKTX) with a Buy rating and announces Price Target of $1.5.
Benzinga Newsdesk

Dati e API: API Benzinga · API notizie azionarie · API valutazioni analisti · API logo aziende

Dati di mercato forniti da API Benzinga

Benzinga

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

© 2026 Benzinga | All Rights Reserved